

Timely, accurate and actionable
molecular diagnostics results

Cyx Solid Tumor 505

Cyx Solid Tumor 505 enables rapid and actionable genomic insights for all patients with advanced cancer. FDA-cleared and CE-IVD-marked comprehensive tumor profiling affords every patient access to personalized treatment options.




Product features

- ✓ **Trustworthy:** FDA-cleared detection chemistry and CE-IVD-marked with overall clinical pass rate of 92.9%
- ✓ **Fast:** Results generated in less than a week via streamlined automation workflow and automated bioinformatics
- ✓ **Actionable:** 505 solid tumor-related genes, including all FDA-approved and professional guideline-supported biomarkers, with easy-to-interpret results
- ✓ **Automated:** On-site automation improves efficiency, consistency, and reduces human errors

Detection chemistry development & validation

- ✓ **Pan solid tumor:** 35 solid tumor types across 9 organ systems
- ✓ **Robust:** >7,300 analytical samples tested
- ✓ **Rigorous:** 15,000 hours of sequencing time
- ✓ **Accurate:** 13 orthogonal methods used for comparison, including PCR, IHC, FISH, RNA and DNA-based NGS approaches



Fast, actionable results

Pathology reports in as little as a week

Assay Specifications

Sample requirements	FFPE Tissue, Slides, or Blocks
Tumor purity minimum	20%
Regions analyzed	Coding regions of 505 genes; non-coding regions for translocations
Mutation Identification	MSI, TMB, Translocations, Indels, SNVs, & Amplifications
Read length	2.23 Mb total
Average total coverage	2,300x

Sample Pathology Report

Ready to Get Started? Call, email, or scan for more info

800-454-2137
info@chronetyx.com

